Cargando…

SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer

AIMS: Lung cancer is one of the most deadly cancers; median survival from diagnosis is less than one year in those with advanced disease. Novel lung cancer biomarkers are desperately needed. In this study, we evaluated SULF2 expression by immunohistochemistry and its association with overall surviva...

Descripción completa

Detalles Bibliográficos
Autores principales: Lui, Natalie S., Yang, Yi-Wei, van Zante, Annemieke, Buchanan, Petra, Jablons, David M., Lemjabbar-Alaoui, Hassan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755530/
https://www.ncbi.nlm.nih.gov/pubmed/26882224
http://dx.doi.org/10.1371/journal.pone.0148911
_version_ 1782416202855874560
author Lui, Natalie S.
Yang, Yi-Wei
van Zante, Annemieke
Buchanan, Petra
Jablons, David M.
Lemjabbar-Alaoui, Hassan
author_facet Lui, Natalie S.
Yang, Yi-Wei
van Zante, Annemieke
Buchanan, Petra
Jablons, David M.
Lemjabbar-Alaoui, Hassan
author_sort Lui, Natalie S.
collection PubMed
description AIMS: Lung cancer is one of the most deadly cancers; median survival from diagnosis is less than one year in those with advanced disease. Novel lung cancer biomarkers are desperately needed. In this study, we evaluated SULF2 expression by immunohistochemistry and its association with overall survival in a cohort of patients with non-small cell lung cancer (NSCLC). We also looked for the presence of SULF2 protein in plasma to evaluate its potential as an early detection biomarker for NSCLC. METHODS: We identified patients who underwent surgical resection for pulmonary adenocarcinoma or squamous cell carcinoma at our institution. A section from each paraffin-embedded specimen was stained with a SULF2 antibody. A pathologist determined the percentage and intensity of tumor cell staining. Survival analysis was performed using a multivariate Cox proportional hazards model. Using a novel SULF2 ELISA assay, we analyzed plasma levels of SULF2 in a small cohort of healthy donors and patients with early stage NSCLC. RESULTS: SULF2 staining was present in 82% of the lung cancer samples. Squamous cell carcinomas had a higher mean percentage of staining than adenocarcinomas (100% vs. 60%; p<0.0005). After adjusting for age, sex, race, histologic type, stage, and neoadjuvant therapy, there was a non-significant (31%; p = 0.65) increase in the risk of death for patients with adenocarcinoma with SULF2 staining in tumor cells. In contrast, there was a significant decrease in the risk of death (89%; p = 0.02) for patients with squamous cell carcinoma with SULF2 staining in tumor cells. SULF2 protein was present in plasma of patients with early stage NSCLC, and soluble SULF2 levels increased with age. Finally, plasma SULF2 levels were significantly elevated in early stage NSCLC patients, compared to healthy controls. CONCLUSIONS: Tumor expression of SULF2 may affect prognosis in NSCLC, while blood SULF2 levels may have a significant role in the diagnosis of this fatal disease.
format Online
Article
Text
id pubmed-4755530
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-47555302016-02-26 SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer Lui, Natalie S. Yang, Yi-Wei van Zante, Annemieke Buchanan, Petra Jablons, David M. Lemjabbar-Alaoui, Hassan PLoS One Research Article AIMS: Lung cancer is one of the most deadly cancers; median survival from diagnosis is less than one year in those with advanced disease. Novel lung cancer biomarkers are desperately needed. In this study, we evaluated SULF2 expression by immunohistochemistry and its association with overall survival in a cohort of patients with non-small cell lung cancer (NSCLC). We also looked for the presence of SULF2 protein in plasma to evaluate its potential as an early detection biomarker for NSCLC. METHODS: We identified patients who underwent surgical resection for pulmonary adenocarcinoma or squamous cell carcinoma at our institution. A section from each paraffin-embedded specimen was stained with a SULF2 antibody. A pathologist determined the percentage and intensity of tumor cell staining. Survival analysis was performed using a multivariate Cox proportional hazards model. Using a novel SULF2 ELISA assay, we analyzed plasma levels of SULF2 in a small cohort of healthy donors and patients with early stage NSCLC. RESULTS: SULF2 staining was present in 82% of the lung cancer samples. Squamous cell carcinomas had a higher mean percentage of staining than adenocarcinomas (100% vs. 60%; p<0.0005). After adjusting for age, sex, race, histologic type, stage, and neoadjuvant therapy, there was a non-significant (31%; p = 0.65) increase in the risk of death for patients with adenocarcinoma with SULF2 staining in tumor cells. In contrast, there was a significant decrease in the risk of death (89%; p = 0.02) for patients with squamous cell carcinoma with SULF2 staining in tumor cells. SULF2 protein was present in plasma of patients with early stage NSCLC, and soluble SULF2 levels increased with age. Finally, plasma SULF2 levels were significantly elevated in early stage NSCLC patients, compared to healthy controls. CONCLUSIONS: Tumor expression of SULF2 may affect prognosis in NSCLC, while blood SULF2 levels may have a significant role in the diagnosis of this fatal disease. Public Library of Science 2016-02-16 /pmc/articles/PMC4755530/ /pubmed/26882224 http://dx.doi.org/10.1371/journal.pone.0148911 Text en © 2016 Lui et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Lui, Natalie S.
Yang, Yi-Wei
van Zante, Annemieke
Buchanan, Petra
Jablons, David M.
Lemjabbar-Alaoui, Hassan
SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer
title SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer
title_full SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer
title_fullStr SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer
title_full_unstemmed SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer
title_short SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer
title_sort sulf2 expression is a potential diagnostic and prognostic marker in lung cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755530/
https://www.ncbi.nlm.nih.gov/pubmed/26882224
http://dx.doi.org/10.1371/journal.pone.0148911
work_keys_str_mv AT luinatalies sulf2expressionisapotentialdiagnosticandprognosticmarkerinlungcancer
AT yangyiwei sulf2expressionisapotentialdiagnosticandprognosticmarkerinlungcancer
AT vanzanteannemieke sulf2expressionisapotentialdiagnosticandprognosticmarkerinlungcancer
AT buchananpetra sulf2expressionisapotentialdiagnosticandprognosticmarkerinlungcancer
AT jablonsdavidm sulf2expressionisapotentialdiagnosticandprognosticmarkerinlungcancer
AT lemjabbaralaouihassan sulf2expressionisapotentialdiagnosticandprognosticmarkerinlungcancer